Blackstone Life Sciences invests $250 million in Anagram Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics to Advance Novel and Patient-Friendly Oral Enzyme Replacement Therapy for Pancreatic Insufficiency
May 7, 2026 8:00 AM EDTPeople with exocrine pancreatic insufficiency currently face highly disruptive pill burden ANG003 expected to only require one tablet per meal
NEW YORK & NATICK, Mass.--(BUSINESS WIRE)-- Blackstone Life Sciences (BXLS) today announced a $250 million investment in Anagram Therapeutics (Anagram), a clinical-stage private biopharmaceutical company dedicated to improving the lives of people living with exocrine pancreatic insufficiency due to cystic fibrosis (CF), pancreatic cancer and related disorders. The investment will help fund the further development, approval and launch of Anagrams ANG003, a novel orally delivered recombinant enzyme replacement therapy that has demonstrated positive clinical data in people with... More
